Biology Reference
In-Depth Information
[24] Allison M. The HER2 testing conundrum. Nat Biotechnol 2010;28:117-19.
[25] Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review
and cost-effectiveness analysis. CMAJ 2007;176:1429-34.
[26] Perez EA, Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest 2008;26:545-52.
[27] Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate
human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 2008;132:1008-15.
[28] Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspec-
tives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84.
[29] Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C. Trastuzumab-associated car-
diac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859-65.
[30] Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1 / B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol 2012;24(2):207-12.
[31] Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
[32] Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
[33] Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene
copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.
Clin Cancer Res 2010;16:291-303.
[34] Saif MW. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs 2010;19:
357-69.
[35] Linardou I, Dahabreh D, Kanaloupiti F, Siannis D, Bafaloukos P, Kosmidis C, et  al. Assessment of somatic
k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review
and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet
Oncol 2008;9:962-72.
[36] Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H. Geitinib or chemotherapy for non-
small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
[37] Saijo N. Targeted therapies: tyrosine-kinase inhibitors - a new standard for NSCLC therapy. Nat Rev Clin
Oncol 2010;7:618-19.
[38] Santini D. Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. Eur
J Cancer Suppl 2008;6:86-90.
[39] Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et  al. K-ras mutations and
beneit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
[40] Mack GS. FDA holds court on post hoc data linking KRAS status to drug response. Nat Biotechnol
2009;27:110-12.
[41] Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an impor-
tant predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in
non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6.
[42] Shankaran V, Obel J, Benson III AB. Predicting response to EGFR inhibitors in metastatic colorectal cancer:
current practice and future directions. Oncologist 2010;15:157-67.
[43] Lopez-Chavez A, Giaccone G. Targeted therapies: importance of patient selection for EGFR TKIs in lung
cancer. Nat Rev Clin Oncol 2010;7:360-2.
[44] Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E, et  al. Analysis of epidermal growth
factor receptor expression as a predictive factor for response to geitinib ('Iressa', ZD1839) in non-small-cell
lung cancer. Br J Cancer 2004;19:208-12.
[45] Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D. Determinants of tumor
response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
[46] Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome
with geitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized
phase III INTEREST trial. J Clin Oncol 2010;28:744-52.
[47] Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Geitinib versus cisplatin plus doc-
etaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor recep-
tor (WJTOG3405): an open label, randomized Phase III trial. Lancet Oncol 2010;11:121-8.
[48] Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Clin Cancer Res 2009;15:7502-9.
Search WWH ::




Custom Search